Pericytes and the Pathogenesis of Diabetic Retinopathy

 

 Buy Article Permissions and Reprints

Abstract

Incipient diabetic retinopathy is characterized by increased vascular permeability and progressive vascular occlusion. Pericyte loss precedes capillary occlusion in the diabetic retina, but its cause remains unclear. One concept proposes that pericyte loss is the result of toxic product accumulation and induction of destructive cellular signals generated within the pericyte. Alternatively, new experimental data indicate that pericyte dropout may result from regulations which induce pericyte elimination as an active process. Pericytes are critical for the development of a proper retinal network, and appear protective for endothelial cells under hyperglycemic conditions. The unifying hypothesis of hyperglycemia-induced microvascular damage centers around hyperglycemia-induced mitochondrial overproduction of reactive oxygen species. The pharmacological prevention of acellular capillaries without the rescue of pericyte loss in experimental diabetic retinopathy suggests that the endothelium is the primary therapeutic target.

References

• 1 Frank R N. Diabetic retinopathy.  N Engl J Med . Jan 1, 2004;  350 (1) 48-58
  PubMedGoogle Scholar
• 2 Lindahl P, Johansson B R, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.  Science. 1997;  277 242-245
  CrossrefPubMedGoogle Scholar
• 3 Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice.  Cytokine Growth Factor Rev. 2004;  15 (4) 215-228
  CrossrefPubMedGoogle Scholar
• 4 Hohman T C, Nishimura C, Robison W G Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries.  Exp Eye Res. 1989;  48 55-60
  CrossrefPubMedGoogle Scholar
• 5 Stitt A W, Li Y M, Gardiner T A, Bucala R, Archer D B, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.  Am J Pathol. 1997;  150 523-531
  PubMedGoogle Scholar
• 6 Mizutani M, Kern T S, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy.  J Clin Invest. 1996;  97 2883-2890
  CrossrefPubMedGoogle Scholar
• 7 Hammes H P, Lin J, Wagner P, Feng Y, vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for. involvement in diabetic retinopathy.  Diabetes. 2004;  53 (4) 1104-1110
  CrossrefPubMedGoogle Scholar
• 8 Allt G, Lawrenson J G. Pericytes: cell biology and pathology.  Cells Tissues Organs. 2001;  169 1-11
  CrossrefPubMedGoogle Scholar
• 9 Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell and Tissue Research 2003 Jul 22
  Google Scholar
• 10 Jain R K. Molecular regulation of vessel maturation.  Nat Med. 2003;  9 (6) 685-693
  CrossrefPubMedGoogle Scholar
• 11 Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom H C, Bergstrom G, Dejana E, Ostman A, Lindahl P, Betsholtz C. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall.  Genes Dev. 2003;  17 1835-1840
  CrossrefPubMedGoogle Scholar
• 12 Hammes H P, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U. Pericytes and the pathogenesis of diabetic retinopathy.  Diabetes. 2002;  51 3107-3112
  CrossrefPubMedGoogle Scholar
• 13 Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi H, Honda Y, Wiegand S J, Yancopoulos G D, Nishikawa S. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells.  J Clin Invest. 2002;  110 1619-1628
  CrossrefPubMedGoogle Scholar
• 14 Cogan D, Toussaint D, Kuwabara T. Retinal vascular pattern. IV. Diabetic retinopathy.  Arch Ophthalmol. 1961;  66 366-378
  PubMedGoogle Scholar
• 15 Little H L, Jack R L, Patz A P, Forsham P H, Ashton N. Pathogenesis of diabetic retinopathy. Diabetic Retinopathy. New York; Thieme-Stratton Inc 1983: 85-106
  Google Scholar
• 16 Engerman R L. Animal models of diabetic retinopathy.  Trans Am Acad Ophthalmol Otolaryngol. 1976;  81 OP710-715
  PubMedGoogle Scholar
• 17 Hammes H P, Wellensiek B, Klöting I, Sickel E, Bretzel R G, Brownlee M B. The relationship of glycemic level to AGE accumulation and retinal pathology in the spontaneous diabetic hamster.  Diabetologia. 1998;  41 165-170
  CrossrefPubMedGoogle Scholar
• 18 Hammes H P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.  Proc Natl Acad Sci USA. 1991;  88 11 555-11 558
  PubMedGoogle Scholar
• 19 Mansour S Z, Hatchell D L, Chandler D, Saloupis P, Hatchell M C. Reduction of basement membrane thickening in diabetic cat retina by sulindac.  Invest Ophthalmol Vis Sci. 1990 Mar 1;  31 (3) 457-463
  PubMedGoogle Scholar
• 20 Enge M, Bjarnegård M, Gerhardt H, Gustafsson E, Kalén M, Asker N, Hammes H P, Shani M, Fässler R, Betsholtz C. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy.  EMBO J. 2002;  21 4307-4316
  CrossrefPubMedGoogle Scholar
• 21 Hellstrom M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.  Development. 1999;  126 3047-3055
  PubMedGoogle Scholar
• 22 Sims D E. Diversity within pericytes.  Clin Exp Pharmacol Physiol. 2000;  27 842-846
  CrossrefPubMedGoogle Scholar
• 23 Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis.  J Cell Biol. 2001;  153 543-553
  CrossrefPubMedGoogle Scholar
• 24 Maisonpierre P C, Suri C, Jones P F, Bartunkova S, Wiegand S J, Radziejewski C, Compton D, McClain J, Aldrich T H, Papadopoulos N, Daly T J, Davis S, Sato T N, Yancopoulos G D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.  Science. 1997;  277 55-60
  CrossrefPubMedGoogle Scholar
• 25 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
  CrossrefPubMedGoogle Scholar
• 26 Nishikawa T, Edelstein D, Du X L, Yamagishi S, Matsumara T, Kaneda Y, Yorek M, Beebe D, Oates P, Hammes H P, Giardino I, Brownlee M. Normalizing Mitochondrial Superoxide Production Blocks Three Major Pathways of Hyperglycemic Damage.  Nature. 2000;  404 787-790
  CrossrefPubMedGoogle Scholar
• 27 Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.  J Clin Invest. 2003 Oct;  112 (7) 1049-1057
  CrossrefPubMedGoogle Scholar
• 28 Hammes H P, Du X, Edelstein D, Taguchi T, Matsumara T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.  Nature Medicine. 2003;  9 294-299
  CrossrefPubMedGoogle Scholar

H.-P. Hammes, M. D.

5. Medical Department, University Hospital Mannheim

Theodor-Kutzer-Ufer 1 - 3 · 68167 Mannheim · Germany

Phone: +49 (621) 383 2663

Fax: +49 (621) 383 2663 ·

Email: hans-peter.hammes@med5.ma.uni-heidelberg.de